INTRODUCTION
============

In order to achieve effective clinical research, scarce research funds must be distributed to appropriate diseases in order to maximize health benefits to the represented population. Systematic approaches to inform research prioritization include identifying and prioritizing research questions, recognizing existing research, and setting goals for primary research ([@B1], [@B2]). A derivative of this approach is to value major diseases, injuries, and risk factors based on their burden to society ([@B3]). Spearheaded by the Institute for Health Metrics and Evaluation (IHME), the Global Burden of Disease (GBD) 2010 Study estimates the burden of 291 diseases and injuries across 187 countries from 1990 to 2010 ([@B4], [@B5]). The metric of disability-adjusted life years (DALYs), in which 1 DALY is equivalent to 1 year of healthy life lost, allows for descriptive global epidemiology of a wide array of disease states. The following ten men's health and urologic diseases (MHUDs) were studied by GBD on the basis of prevalence, common case definitions, and data availability: tubulointerstitial nephritis, pyelonephritis, and urinary tract infections; kidney and other urinary organ cancers; urolithiasis; male infertility; benign prostatic hyperplasia; prostate cancer; testicular cancer; hydrocele due to lymphatic filariasis; dysuria/bladder pathology/hydronephrosis due to schistosomiasis; and bladder cancer ([Figure-1](#f01){ref-type="fig"}).

Figure 1Square pie chart representing percent of total DALY for ten men's health and urologic diseases; area of each square/rectangle represents percentage of total burden.**green =** non-infectious conditions, **red =** infectious conditions, and **blue =** neoplastic conditions

Systematic reviews are the cornerstone of evidence-based medicine, yet few efforts have been made to assess whether the prioritization of systematic reviews reflect global disease burden ([@B6]). The Cochrane Database of Systematic Reviews (CDSR) produces systematic reviews and protocols (published proposals for future systematic reviews) across all medical specialties as well as health systems, public health, and child development. Cochrane systematic reviews undergo exhaustive editorial processing, are more methodologically rigorous, and are updated more frequently than non-Cochrane reviews and paper-based journals ([@B7], [@B8]). Prior studies have evaluated the association between broad categories of disease burden with randomized trials and Cochrane systematic reviews ([@B9]-[@B12]). This study will assess whether the CDSR representation of ten MHUDs corresponds to GBD 2010 disability estimates.

MATERIALS AND METHODS
=====================

ICD-10 code definitions for the ten MHUDs have been previously published and were used to generate search terms, which were entered into the "title, abstract, keywords" CDSR search function ([@B5], [@B13]). Systematic reviews and protocols were considered to determine MHUD representation in CDSR, according to abstract subject content. Online publication date, the number of studies included in each systematic review, and the particular Cochrane review group that published the review or protocol were collected.

Two authors (T.O and H.P.) collected data independently during February 2015. DALY metrics for each of the ten MHUDs, expressed as percentages of total DALY's of all 291 conditions measured in GBD 2010, were obtained from the GBD Compare interactive time plot, available at \<http://viz.healthmetricsandevaluation.org/gbd-compare/\>. Spearman rank correlation analysis was performed to assess statistical dependence between CDSR representation and disease burden. Rho, a coefficient ranging from-1 (strong negative correlation) to +1 (strong positive correlation), is interpreted with a two-tailed p-value. A line-of-best-fit was also generated between CDSR representation and % of total DALYs.

As this study did not involve human subjects, institutional review board approval was not necessary.

RESULTS
=======

Nine of the ten MHUD conditions studied in GBD 2010 were represented by at least one systematic review. A total of 116 systematic reviews and protocols published by nine Cochrane review groups represented the ten MHUDs (Supporting [Tables 1](#t2){ref-type="table"} and [2](#t3){ref-type="table"} for included and excluded titles, respectively). The majority of reviews and protocols covered tubulointerstitial nephritis, pyelonephritis, and urinary tract infections (n=46). Hydrocele due to lymphatic filariasis had no representation in CDSR. Of the ten MHUDs, benign prostatic hyperplasia had the greatest global disease burden (0.2%) while male infertility had the lowest (0.007%) [Table-1](#t1){ref-type="table"}.

Table 1Men's health and urologic diseases studied by GBD 2010 with corresponding ICD-10 codes, search terms, number of systematic reviews (R) and protocols (P) in CDSR, percent of total DALYs (arranged in order of decreasing % of total DALY), and number of studies included in Cochrane reviews.ConditionICD-10 codeSearch termsNumber of cochrane reviews (R) & protocols (P)% total 210 dalys (out of 291 conditions)Number of studies in cochrane reviewBenign prostatic hyperplasiaN40"benign prostatic hyperplasia" "median bar" "prostatic hyperplasia" "adenofibromatous hypertrophy of prostrate" "hypertrophy of prostate "prostatic obstruction"9 (7 R, 2 P)0.2%35Prostate cancerC61, D07.5, D40.0"prostate cancer" "prostatic carcinoma in situ" "prostate neoplasm"23 (22 R, 1 P)0.15%411Kidney and other urinary organ cancersC64-C66, D41.0-D41.2"kidney cancer" "neoplasm of the ureter" "neoplasm of the kidney" "neoplasm of the renal pelvis"4 (4 R)0.15%63Tubulointerstitial nephritis, pyelonephritis, and urinary tract infectionsN10-N12, N15.1-N15.9, N30, N34, N39.0"tubulointerstitial nephritis" "pyelonephritis" "urinary tract infections" "infectious interstitial nephritis" "pyelitis" "balkan nephropathy" "renal and perinephric abscess" "cystitis" "trigonitis" "urethral abscess" "urethritis"46 (41 R, 5 P)0.13%529Bladder cancerC67, D09.0\*, D41.4"bladder cancer" "bladder carcinoma" "bladder neoplasm"11 (10 R, 1 P)0.12%106Hydrocele due to lymphatic filariasisB74 (except B74.3, B74.4, B74.8, B74.9)"lymphatic filariasis" \[hydrocele\]00.064%0UrolithiasisN20-N23"urolithiasis" "urinary stones" "nephrolithiasis" "kidney stones" "ureterolithiasis" "cystolithiasis" "bladder stones"10 (8 R, 2 P)0.045%59Dysuria/bladder pathology/hydronephrosis due to schistosomiasisB65"schistosomiasis" \[dysuria, bladder, hydronephrosis\]4 (2 R, 2 P)0.034%35Testicular cancerC62, D40.1"testicular cancer" "malignant neoplasm of testis"1 R0.013%0Male infertilityN46"azoospermia" "oligospermia"8 R0.00795

Supporting Table 1Injury or TraumaReview (R) or Protocol (P) TitleCochrane GroupNumber of StudiesYear of Online PublicationTubulo-interstitial nephritis, pyelonephritis, and urinary tract infectionsAntibiotics for acute pyelonephritis in children (R)Renal Group272007 Antibiotics for asymptomatic bacteriuria in pregnancy (R)Pregnancy and Childbirth Group142007 Treatments for symptomatic urinary tract infections during pregnancy (R)Pregnancy and Childbirth Group102011 Duration of treatment for asymptomatic bacteriuria during pregnancy (R)Pregnancy and Childbirth Group132011 Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes (R)Renal Group02015 Procalcitonin , C-reactive protein , and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children (R)Renal Group172015 Duration of antibacterial treatment for uncomplicated urinary tract infection in women (R)Renal Group322005 Interventions for preventing recurrent urinary tract infection during pregnancy (R)Pregnancy and Childbirth Group12012 Long-term antibiotics for preventing recurrent urinary tract infection in children (R)Renal Group122011 Treatments for symptomatic urinary tract infections during pregnancy (R)Pregnancy and Childbirth Group102011 Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies (R)Incontinence Group92012 Types of indwelling urethral catheters for short-term catheterization in hospitalized adults (R)Incontinence Group262014 Antibiotics for treating lower urinary tract infection in children (R)Renal Group162012 Methenamine hippurate for preventing urinary tract infections (R)Renal Group132012 Estrogens for preventing recurrent urinary tract infection in postmenopausal women (R)Renal Group92008 Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children (R)Renal Group102003 Urinary catheter policies for long-term bladder drainage (R)Incontinence Group82012 Antimicrobial agents for treating uncomplicated urinary tract infection in women (R)Renal Group212010 Modes of administration of antibiotics for symptomatic severe urinary tract infections (R)Renal Group152007 Antibiotic duration for treating uncomplicated , symptomatic lower urinary tract infections in elderly women (R)Renal Group152008 Antibiotic prophylaxis for short-term catheter bladder drainage in adults (R)Incontinence Group62013 Cranberries for treating urinary tract infections (R)Renal Group01998 Antibiotics for preventing recurrent urinary tract infection in non-pregnant women (R)Renal Group192004 Cranberries for preventing urinary tract infections (R)Renal Group242012 Routine neonatal circumcision for the prevention of urinary tract infections in infancy (R)Neonatal Group02012 Urinary catheter policies for short-term bladder drainage in adults (R)Incontinence Group172005 Intermittent catheterization for long-term bladder management (R)Incontinence Group312014 Antibiotic prophylaxis for transrectal prostate biopsy (R)Prostatic Diseases and Urologic Cancers Group192011 Short term urinary catheter policies following urogenital surgery in adults (R)Incontinence Group392006 Washout policies in long-term indwelling urinary catheterization in adults (R)Incontinence Group52010 Routine intraoperative ureteric stenting for kidney transplant recipients (R)Renal Group72013 Interventions for primary vesicoureteric reflux (R)Renal Group202011 Types of indwelling urinary catheters for long-term bladder drainage in adults (R)Incontinence Group32012 Laser prostatectomy for benign prostatic obstruction (R)Prostatic Diseases and Urologic Cancers Group202000 Quinolones for uncomplicated acute cystitis in women (R)Renal Group112006 Drugs for treatment of urinary retention after surgery in adults (R)Incontinence Group72010 Indwelling bladder catheterization as part of intraoperative and postoperative care for caesarean section (R)Pregnancy and Childbirth Group52014 Dietary interventions for preventing complications in idiopathic hypercalciuria (R)Renal Group52014 Interventions for covert bacteriuria in children (R)Renal Group32012 Pharmacological interventions for preventing complications in idiopathic hypercalciuria (R)Renal Group52009 Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy (R)Pregnancy and Childbirth Group52010 Urinary alkalization for uncomplicated urinary tract infection (P)Renal GroupN/A2013 Dimercaptosuccinic acid scan versus ultrasound in screening for vesicoureteral reflux among children with urinary tract infections (P)Renal GroupN/A2013 Chinese herbal medicine for treating recurrent urinary tract infections in women (P)Renal GroupN/A2013 Probiotics for preventing urinary tract infection in people with neuropathic bladder (P)Renal GroupN/A2013 Probiotics for preventing urinary tract infections in adults and children (P)Renal GroupN/A2010Kidney and other urinary organ cancersTargeted therapy for advanced renal cell carcinoma (R)Prostatic Diseases and Urologic Cancers Group252008 Immunotherapy for advanced renal cell cancer (R)Prostatic Diseases and Urologic Cancers Group372004 Surgical management of localized renal cell carcinoma (R)Prostatic Diseases and Urologic Cancers Group02010 Surgical management for upper urinary tract transitional cell carcinoma (R)Prostatic Diseases and Urologic Cancers Group12011UrolithiasisExtracorporeal shock wave lithotripsy (ESWL ) versus percutaneous nephrolithotomy (PCNL ) or retrograde intrarenal surgery (RIRS ) for kidney stones (R)Renal Group52014 Dietary interventions for preventing complications in idiopathic hypercalciuria (R)Renal Group52014 Extracorporeal shock wave lithotripsy (ESWL ) versus ureteroscopic management for ureteric calculi (R)Renal Group72012 Pharmacological interventions for preventing complications in idiopathic hypercalciuria (R)Renal Group52009 Fluids and diuretics for acute ureteric colic (R)Renal Group22012 Water for preventing urinary stones (R)Renal Group12012 Alpha-blockers as medical expulsive therapy for ureteral stones (R)Renal Group322014 Percussion , diuresis , and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsy (R)Renal Group22013 Analgesia for patients undergoing shockwave lithotripsy for urinary stones (P)Renal GroupN/A2012 Interventions for treating urinary stones in children (P)Renal GroupN/A2013Male infertilityIntra-uterine insemination for male subfertility (R)Menstrual Disorders and Subfertility Group82007 Antioxidants for male subfertility (R)Menstrual Disorders and Subfertility Group482014 Surgery or embolization for varicoceles in subfertile men (R)Menstrual Disorders and Subfertility Group102012 Regular (ICSI ) versus ultra-high magnification (IMSI ) sperm selection for assisted reproduction (R)Menstrual Disorders and Subfertility Group92013 Intra-uterine insemination for unexplained subfertility (R)Menstrual Disorders and Subfertility Group82012 Techniques for surgical retrieval of sperm prior to intra-cytoplasmic sperm injection (ICSI ) for azoospermia (R)Menstrual Disorders and Subfertility Group22008 Cervical insemination versus intra-uterine insemination of donor sperm for subfertility (R)Menstrual Disorders and Subfertility Group42008 Gonadotrophins for idiopathic male factor subfertility (R)Menstrual Disorders and Subfertility Group62013Benign prostatic hyperplasiaPygeum africanum for benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group181998 Finasteride for benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group232010 Beta-sitosterols for benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group41999 Serenoa repens for benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group322012 Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group   Microwave thermotherapy for benign prostatic hyperplasia (R)Prostatic Diseases and Urologic Cancers Group152012 Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia (P)Prostatic Diseases and Urologic Cancers GroupN/A2012 Laser prostatectomy for benign prostatic obstruction (R)Prostatic Diseases and Urologic Cancers Group202000 Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (P)Prostatic Diseases and Urologic Cancers GroupN/A2014Prostate cancer5-alpha-reductase inhibitors for prostate cancer prevention (R)Prostatic Diseases and Urologic Cancers Group92008 Screening for prostate cancer (R)Prostatic Diseases and Urologic Cancers Group52013 Lycopene for the prevention of prostate cancer (R)Prostatic Diseases and Urologic Cancers Group32011 Psychosocial interventions for men with prostate cancer (R)Prostatic Diseases and Urologic Cancers Group192013 Radical prostatectomy versus watchful waiting for prostate cancer (R)Prostatic Diseases and Urologic Cancers Group22010 Bisphosphonates for advanced prostate cancer (R)Prostatic Diseases and Urologic Cancers Group102006 Cryotherapy for localized prostate cancer (R)Prostatic Diseases and Urologic Cancers Group82007 Neo- adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer (R)Prostatic Diseases and Urologic Cancers Group212006 Early versus deferred androgen suppression in the treatment of advanced prostatic cancer (R)Prostatic Diseases and Urologic Cancers Group42001 Chemotherapy for hormone-refractory prostate cancer (R)Prostatic Diseases and Urologic Cancers Group472006 Maximal androgen blockade for advanced prostate cancer (R)Prostatic Diseases and Urologic Cancers Group201999 Adjuvant radiotherapy following radical prostatectomy for prostate cancer (R)Prostatic Diseases and Urologic Cancers Group32011 Intermittent versus continuous androgen suppression for prostatic cancer (R)Prostatic Diseases and Urologic Cancers Group52007 Low-dose rate brachytherapy for men with localized prostate cancer (R)Prostatic Diseases and Urologic Cancers Group12011 Interventions for sexual dysfunction following treatments for cancer (R)Pain, Palliative and Supportive Care Group112007 Selenium for preventing cancer (R)Gynaecological Cancer Group552014 Green tea (Camellia sinensis) for the prevention of cancer (R)Gynaecological Cancer Group512009 Exercise for the management of cancer-related fatigue in adults (R)Pain, Palliative and Supportive Care Group562012 Laparoscopic versus open prostatectomy for the treatment of localized prostate cancer (P)Prostatic Diseases and Urologic Cancers GroupN/A2012 Non-steroidal antiandrogen monotherapy compared with luteinizing hormone --releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (R)Prostatic Diseases and Urologic Cancers Group112014 Conservative management for postprostatectomy urinary incontinence (R)Incontinence Group502015 Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery (R)Incontinence Group12014 Antibiotic prophylaxis for transrectal prostate biopsy (R)Prostatic Diseases and Urologic Cancers Group192011Testicular cancerScreening for testicular cancer (R)Prostatic Diseases and Urologic Cancers Group02011Bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancer (R)Prostatic Diseases and Urologic Cancers Group62012 Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer (R)Prostatic Diseases and Urologic Cancers Group52011 Gemcitabine for unresectable , locally advanced or metastatic bladder cancer (R)Prostatic Diseases and Urologic Cancers Group62011 Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer (R)Prostatic Diseases and Urologic Cancers Group62000 Neo-adjuvant chemotherapy for invasive bladder cancer (R)Prostatic Diseases and Urologic Cancers Group112004 Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer (R)Prostatic Diseases and Urologic Cancers Group72003 Surgery versus radiotherapy for muscle invasive bladder cancer (R)Prostatic Diseases and Urologic Cancers Group32001 Adjuvant chemotherapy for invasive bladder cancer (individual patient data) (R)Prostatic Diseases and Urologic Cancers Group62006 Green tea (Camellia sinensis) for the prevention of cancer (R)Gyanecological Cancer Group512009 Perioperative nutrition for the treatment of bladder cancer by radical cystectomy (P)Prostatic Diseases and Urologic Cancers GroupN/A2012 Urinary diversion and bladder reconstruction /replacement using intestinal segments for intractable incontinence or following cystectomy (R)Incontinence Group52012Hydrocele due to lymphatic filariasis    Dysuria/bladder pathology/hydronephrosis due to schistosomiasisDrugs for treating urinary **schistosomiasis** (R)Infectious Diseases Group302014 Therapeutic and prophylactic drug interventions for **Schistosomiasis** japonicum (P)Infectious Diseases GroupN/A2012 Rapid screening and diagnostic tests for human **schistosomiasis** in endemic areas (P)Infectious Diseases GroupN/A2012 Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy (R)Incontinence Group52012

Supporting Table 2:ConditionReview (R) or Protocol (P)Tubulo-interstitial nephritis, pyelonephritis, and urinary tract infectionsInterventions to improve professional adherence to guidelines for prevention of device-related infections (R) Mechanical dilatation of the cervix at non-labour caesarean section for reducing postoperative morbidity (R) Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section (R) Traditional suburethral sling operations for urinary incontinence in women (R) Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures (R) Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers (R) Rituximab for relapsing-remitting multiple sclerosis (R) Beta lactam antibiotic monotherapy versus beta lactam -aminoglycoside antibiotic combination therapy for sepsis (R) Habit retraining for the management of urinary incontinence in adults (R) Preoperative skin antiseptics for preventing surgical wound infections after clean surgery (R) Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding (R) Antimicrobial therapy for chronic bacterial prostatitis (R) Cyanoacrylate microbial sealants for skin preparation prior to surgery (R) Perioperative increase in global blood flow to explicit defined goals and outcomes following surgery (R) Interventions to improve antibiotic prescribing practices in ambulatory care (R) Teriflunomide for multiple sclerosis (R) Laquinimod for multiple sclerosis (R) Mitoxantrone for multiple sclerosis (R) Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1 (R) Surgical approach to hysterectomy for benign gynecological disease (R) Interventions for preventing mastitis after childbirth (R) Laparoscopy versus laparotomy for benign ovarian tumor (R) Valproate preparations for agitation in dementia (R) Regional versus general anesthesia for caesarean section (R) Interventions for promoting the initiation of breastfeeding (R) Protocolized versus non- protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients (R) In-hospital care pathways for stroke (R) Schedules for home visits in the early postpartum period (R) Short term benefits for laparoscopic colorectal resection (R) Diaphragm versus diaphragm with spermicides for contraception (R) Cervical cap versus diaphragm for contraception (R)Kidney and other urinary organ cancersEarly and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer (R) Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer (R) Bisphosphonates and other bone agents for breast cancer (R) Interventions for preventing non-melanoma skin cancers in high-risk groups (R) Perioperative blood transfusions and recurrence of colorectal cancer (R) Medical interventions for the prevention of platinum-induced hearing loss in children with cancer (R) Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer (R) Immunosuppressive T-cell antibody induction for heart transplant recipients (R) Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix (R) Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (R) HMG CoA reductase inhibitors (statins) for dialysis patients (R) Urinary diversion and bladder reconstruction /replacement using intestinal segments for intractable incontinence or following cystectomy (R) Pharmacological interventions for pruritus in adult palliative care patients (R) Homocysteine-lowering interventions for preventing cardiovascular events (R) HMG CoA reductase inhibitors (statins ) for kidney transplant recipients (R) Vitamin D supplementation for prevention of mortality in adults (R) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (R) Antibody induction therapy for lung transplant recipients (R) First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma , a systematic review of controlled studies (R) Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis (R) Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients (R) Bisphosphonates in multiple myeloma: a network meta-analysis (R) Darbepoetin for the anemia of chronic kidney disease (R) Selenium for preventing cancer (R) Hyperbaric oxygenation for tumor sensitization to radiotherapy (R) Adjuvant radiotherapy following radical prostatectomy for prostate cancer (R) Exenterative surgery for recurrent gynecological malignancies (R) Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer (R) Laparoscopy versus laparotomy for the management of early stage endometrial cancer (R) Laparoscopic versus open total mesorectal excision for rectal cancer (R) Adjuvant radiotherapy for stage I endometrial cancer (R) Cryotherapy for localized prostate cancer (R) Spinal cord stimulation for cancer -related pain in adults (R) Chemoradiation for advanced primary vulval cancer (R) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (R) Surgical management for upper urinary tract transitional cell carcinoma (R) Cholecystectomy for patients with silent gallstones (R) Drugs for treating urinary schistosomiasis (R) Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis (R) Cranberries for preventing urinary tract infections (R) Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases (R) Conservative management for postprostatectomy urinary incontinence (R) Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery (R) The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men (R)UrolithiasisPegloticase for chronic gout (R) Fluids and diuretics for acute ureteric colic (R) Vitamin D supplementation for prevention of mortality in adults (R) Chinese medicinal herbs for cholelithiasis (R) Thyroid hormones for acute kidney injury (R) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (R)Male infertilityIntra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in couples with non-male subfertility (R) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (R) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (R) Intrauterine insemination versus fallopian tube sperm perfusion for non-tubal infertility (R) Vasectomy occlusion techniques for male sterilization (R) Steroid hormones for contraception in men (R)Benign prostatic hyperplasiaInterventions for chronic abacterial prostatitis (R)Prostate cancerInterventions for improving the adoption of shared decision making by healthcare professionals (R)Testicular cancerChemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease (R)Bladder cancerCholecystectomy for patients with silent gallstones (R) Hyperbaric oxygenation for tumor sensitization to radiotherapy (R) Drugs for treating urinary schistosomiasis (R) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (R) Adjuvant radiotherapy for stage I endometrial cancer (R) Laparoscopy versus laparotomy for the management of early stage endometrial cancer (R) Selenium for preventing cancer (R) Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases (R) Chemoradiation for advanced primary vulval cancer (R) Laparoscopic versus open total mesorectal excision for rectal cancer (R) Spinal cord stimulation for cancer-related pain in adults (R)Hydrocele due to lymphatic filariasisAlbendazole for lymphatic filariasis (R) Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis (R)Dysuria/bladder pathology/hydronephrosis due to schistosomiasisMetrifonate for Alzheimer\'s disease (R) Drugs for treating Schistosoma mansoni infection (R)

Reviews and protocols representing the ten MHUDs were published by the following Cochrane review groups: Prostatic Diseases and Urologic Cancers Group (n=43); Renal Group (36); Incontinence Group ([@B14]); Menstrual Disorders and Subfertility Group ([@B8]); Pregnancy and Childbirth Group ([@B7]); Infectious Diseases Group ([@B3]); Pain, Palliative and Supportive Care Group ([@B2]); Gynecological Cancer Group ([@B2]); and Neonatal Group ([@B1]).

Spearman rank correlation testing between CDSR representation and DALY metrics revealed poor positive correlation that was statistically insignificant (rho=0.41, p=0.21). The majority of the MHUDs ([@B6]) were under-represented in CDSR as compared to GBD DALY ([Figure-2](#f02){ref-type="fig"}). Most of the systematic reviews and protocols (58.6%) were published from 2011 to 2015 while 37.9% were published from 2000 to 2010; only 4 reviews were published prior to 2000. Maintaining systematic reviews up-to-date is critical to deliver consensus statements on current world literature that ultimately impact clinical decisions and patient outcomes.

Figure 2Comparison of men's health and urologic disease representation in the Cochrane Database of Systematic Reviews with percent of 2010 DALYs from 291 conditions studied by GBD 2010.

Representation of tubulointerstitial nephritis, pyelonephritis, and urinary tract infections exceeded GBD disease burden. This disease category also had the greatest number of cumulative studies informing its systematic reviews (529). The one systematic review representing testicular cancer, entitled "Screening for testicular cancer," found no randomized controlled trials in the literature. Systematic reviews that find no suitable trials to address their objectives uncover areas for much-needed, high-quality research.

The World Health Organization (WHO) classifies two of the MHUDs as neglected tropical diseases: dysuria/bladder pathology/hydronephrosis due to schistosomiasis and hydrocele due to lymphatic filariasis ([@B14]). It is important to note that just as the DALY metrics reported for these two diseases include only burden due to the MHUD morbidity (dysuria, bladder pathology, hydronephrosis, hydrocele), systematic reviews were only considered representative if they included assessment of the MHUD pathology.

DISCUSSION
==========

We acknowledge several limitations of our study. The scope of CDSR systematic reviews is subject to variability. For instance, authors may prepare one large review of multiple interventions (lumping) or several reviews of individual interventions (splitting). Therefore, treating a systematic review or protocol as one measurement unit may not be entirely accurate for every topic. While beyond the scope of this limited study, further exploration is warranted into potential underrepresentation of certain conditions.

There remains a lack of transparency in publications and databases on the quality of data and criteria involved in prioritization decisions ([@B15]). Other important factors in priority setting include availability of research funds, knowledge gap, and impact on disadvantaged populations. Research prioritization is also inherently political and dependent on financial backing, which further demonstrates the importance of a transparent process. Attention and awareness of priority setting has the potential to minimize research disparities and, ultimately, impact populations at a global scale.
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